Trial reportArthritis research & therapy2005
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].
Trial report in Arthritis research & therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05204836 (Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention), which is not on this map. Cited by 94 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention
Who cites it
94 citing papers in PubMed, 6 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- The Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis-a Systematic Review and Network Meta-Analysis.Journal of general internal medicine · 2021Pooled it
- Risk factors for pain and functional impairment in people with knee and hip osteoarthritis: a systematic review and meta-analysis.BMJ open · 2020Pooled it
- Pooled it
- Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review.PloS one · 2013Pooled it
- Responsiveness to change and reliability of measurement of radiographic joint space width in osteoarthritis of the knee: a systematic review.Osteoarthritis and cartilage · 2011Pooled it
- Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.BMC musculoskeletal disorders · 2008Pooled it
- Trial
- A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients - ZAP2.BMC musculoskeletal disorders · 2018Trial
- Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.Journal of translational medicine · 2018Trial
- A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis.BMC musculoskeletal disorders · 2017Trial
- The effect of vitamin D supplementation on knee osteoarthritis, the VIDEO study: a randomised controlled trial.Osteoarthritis and cartilage · 2016Trial
- Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial.Rheumatology international · 2015Trial
- Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study.Annals of the rheumatic diseases · 2014Trial
- Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.Clinical rheumatology · 2013Trial
- Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.Journal of bone and mineral metabolism · 2011Trial
- Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial.Journal of bone and mineral metabolism · 2008Trial
- Decreased incidence of shoulder arthroplasty in patients prescribed anti-resorptive therapy for osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Osteocyte parvalbumin mediates mechanotransduction to attenuate osteoarthritis.Nature communications · 2026Article
- Article
- Weight loss ameliorates symptoms of osteoarthritis and is correlated with alterations in soluble bone and cartilage markers: an analysis of patient-reported outcomes and biomarkers.BMC rheumatology · 2026Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine the efficacy and safety of risedronate in patients with knee osteoarthritis (OA), the British study of risedronate in structure and symptoms of knee OA (BRISK), a 1-year prospective, double-blind, placebo-controlled study, enrolled patients (40-80 years of age) with mild to moderate OA of the medial compartment of the knee. The primary aims were to detect differences in symptoms and function. Patients were randomized to once-daily risedronate (5 mg or 15 mg) or placebo. Radiographs were taken at baseline and 1 year for assessment of joint-space width using a standardized radiographic method with fluoroscopic positioning of the joint. Pain, function, and stiffness were assessed using the Western Ontario and McMaster Universities (WOMAC) OA index. The patient global assessment and use of walking aids were measured and bone and cartilage markers were assessed. The intention-to-treat population consisted of 284 patients. Those receiving risedronate at 15 mg showed improvement of the WOMAC index, particularly of physical function, significant improvement of the patient global assessment (P < 0.001), and decreased use of walking aids relative to patients receiving the placebo (P = 0.009). A trend towards attenuation of joint-space narrowing was observed in the group receiving 15 mg risedronate. Eight percent (n = 7) of patients receiving placebo and 4% (n = 4) of patients receiving 5 mg risedronate exhibited detectable progression of disease (joint-space width >or= 25% or >or= 0.75 mm) versus 1% (n = 1) of patients receiving 15 mg risedronate (P = 0.067). Risedronate (15 mg) significantly reduced markers of cartilage degradation and bone resorption. Both doses of risedronate were well tolerated. In this study, clear trends towards improvement were observed in both joint structure and symptoms in patients with primary knee OA treated with risedronate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.